肢体肿瘤手术假体置换重建后再手术的原因与频率:一项系统综述
该系统综述检索了1998年4月15日至2018年4月15日发表的49项研究,共2721例原发性肢体骨肉瘤切除后行假体置换重建的患者,再手术率为47%,机械性事件占33%,深部感染需取出假体者占9%,局部复发需翻修或截肢者占5%。作者结论认为假体失败常见,证据质量低且失访率高。
要点
- 2721例患者中再手术1283例(47%),机械性事件907例(33%)。
- 深部感染需取出初始假体247例(9%),局部复发需翻修或截肢129例(5%)。
- 无任何外科再干预的假体总生存率在报告研究中平均随访79个月时为63%。
核心结论
- 肢体肿瘤术后假体置换重建失败常见,最常由假体磨损或断裂、无菌性松动和感染引起。
- 深部感染不可保留假体似多发生在术后约2年,无菌性松动最常发生在75个月。
- 已发表证据质量低,失访率高且再干预时间报告不一致,限制研究间分析。
研究设计与样本
- 系统检索MEDLINE、Embase和Cochrane Library从1998年4月15日至2018年4月15日发表的所有研究。
- 三位评价者独立筛选报告原发性肢体骨肿瘤假体置换重建生存和需翻修事件的研究并进行独立数据提取。
- 排除患者少于5例的研究、所有系统综述/Meta分析以及未报告原发性肢体骨肿瘤的研究。
- 共49项研究符合纳入标准,初始检索返回904项研究,无随机对照试验。
- 总患者2721例,平均随访93个月(范围1-516个月),2118例中447例(21%)失访或死亡,6项研究未提供失访数据。
主要发现
- 2721例患者中再手术1283例(47%)。
- 因机械性假体事件(软组织裂开或关节周围软组织不稳、无菌性松动或假体磨损/断裂)再手术907/2721例(33%)。
- 无菌性松动发生在315例中的212例(67%),平均75个月(范围1-376个月)。
- 深部感染需取出初始假体发生在247/2721例(9%),在有感染时间数据的190例感染中(77%),深部感染平均发生在24个月(范围1-372个月)。
- 需翻修或截肢的局部复发率在所有患者中为129例(5%)。
关键数值与推荐
- MINORS平均评分:前瞻性研究14分,回顾性研究11分。
- 证据等级:Level IV,治疗性研究。
临床怎么用
- 原文未据此给出推荐。
局限性
- 已发表证据质量低,失访率高且再干预时间报告不一致,限制研究间分析。
- 无随机对照试验。
- 6项研究未提供失访数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Excision of bone tumors and endoprosthetic reconstruction allow patients early weightbearing and a potential functional advantage compared with amputation. These reconstructions do not restore the limb to normal status, however, and patients are subject to complications that may result in revision or loss of the limb. Because better understanding of these complications based on current information might help the patient and surgeon in decision-making, we undertook a systematic review of studies published on this topic. QUESTIONS/PURPOSES: (1) What are the primary modes and proportion of failure of tumor endoprostheses in patients undergoing reconstruction after excision of primary extremity bone sarcomas? METHODS: We systematically searched MEDLINE, Embase, and the Cochrane Library for all studies published from April 15, 1998, to April 15, 2018. Three reviewers independently reviewed studies reporting endoprosthetic reconstruction survival and events requiring revision for primary extremity bone tumors treated with endoprosthetic reconstruction for inclusion and performed independent data extraction. We excluded all studies with fewer than five patients, any systematic review/meta-analyses, and any study not reporting on primary extremity bone tumors. All discrepancies were resolved by the study's senior author. Data extracted from included studies were any reoperation event for wound dehiscence, any operative fixation for a pathologic fracture, and any revision of the primary endoprosthesis for implant wear or breakage, deep infection not amenable to prosthesis retention, or for local recurrence. We assessed the overall quality of the evidence with the Methodological Index for Non-Randomized Studies (MINORS) approach with a higher MINORS score representative of a more methodologically rigorous study with a total possible score of 16 points for noncomparative and 24 points for comparative studies. Forty-nine studies met criteria for inclusion from an initial search return of 904 studies, of which no studies were randomized controlled trials. From a total patient population of 2721, there was a mean followup of 93 months (range, 1-516 months) with loss to followup or death occurring in 447 of 2118 (21%) patients with six studies not providing loss to followup data. The mean MINORS score was 14 for prospective studies and 11 for retrospective studies. RESULTS: Overall, there were 1283 reoperations among the 2721 (47%) patients. Reoperation for mechanical endoprosthetic events (soft tissue dehiscence or periarticular soft tissue instability, aseptic loosening, or implant wear/fracture) occurred in 907 of 2721 (33%) patients. Aseptic loosening occurred at a mean of 75 months (range, 1-376 months) in 212 of 315 patients (67%). Deep infection requiring removal of the initial prosthesis occurred in 247 of 2721 (9%) patients with deep infection occurring at a mean of 24 months (range, 1-372 months) in the 190 infections (77%) with time to infection data available. Local recurrence rates requiring revision or amputation occurred in 129 (5%) of all patients. There was an overall primary endoprosthesis survival rate without any surgical reintervention of 63% among reporting studies at a mean of 79 months followup. CONCLUSIONS: Failures of endoprosthetic reconstructions after extremity tumor surgery are common, most often resulting from implant wear or fracture, aseptic loosening, and infection. Importantly, the aggregated data are the first to attempt to quantify the time to specific complication types within this patient population. Deep infection not amenable to endoprosthesis retention appears to occur approximately 2 years postoperatively in most patients, with aseptic loosening occurring most commonly at 75 months. Although endoprosthetic reconstruction is one of the most common forms of reconstruction after bone tumor resection, the quality of published evidence regarding this procedure is of low quality with high loss to followup and data quality limiting interstudy analysis. The quality of the evidence is low with high loss to followup and inconsistent reporting of times to reintervention events. Although the most common modes of endoprosthetic failure in this population are well known, creation of quality prospective, collaborative databases would assist in clarifying and informing important elements of the followup process for these patients. LEVEL OF EVIDENCE: Level IV, therapeutic study.
引用
- Thornley P, Vicente M, MacDonald A, et al. Causes and Frequencies of Reoperations After Endoprosthetic Reconstructions for Extremity Tumor Surgery: A Systematic Review. Clin Orthop Relat Res. 2019. PMID: 30801278. doi:10.1097/CORR.0000000000000630
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。